The FDA has issued its first approval for datopotamab deruxtecan-dlnk, a targeted therapy, for certain types of breast cancer. The U.S. Food and Drug Administration (FDA) has approved datopotamab deruxtecan-dlnk (dato-DXd; Datroway) for the...
Cancer incidence on the rise in younger women, and a new report issued on alcohol and health.
The FDA approved sotorasib and panitumumab for metastatic colorectal cancer with the KRAS G12C mutation. The U.S. Food and Drug Administration (FDA) approved sotorasib (Lumakras) in combination with panitumumab (Vectibix) for the treatment of...
Acalabrutinib was granted traditional approval as a monotherapy for previously treated MCL and as part of a combination for untreated MCL. The U.S. Food and Drug Administration (FDA) has granted traditional approval to acalabrutinib...
Researchers share lessons from the first oncology clinical trial in Trinidad, which involved a patient named Faith Hill.
At the 2024 San Antonio Breast Cancer Symposium, researchers discussed clinical trials for vaccines and other ways to prevent breast cancer.
New research indicates that adding immunotherapy to muscle-invasive bladder cancer treatment can improve event-free and overall survival.
Getting more calcium could lower risk for colorectal cancer, and research provides new insight into which BRCA2 mutations can lead to cancer.
Our annual Experts Forecast offers insights from AACR President-Elect Lillian Siu, John E. Dick, Regina Barzilay, Vinod Balachandran, and Scarlett Lin Gomez.
Androgen deprivation therapy, a common prostate cancer treatment, may increase cognitive difficulties.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now